I will provide a biotech expert interview and research support
Biotech Consultant Cell and Gene Therapy CRISPR mRNA and IND Strategy
About this Gig
Need an independent biotech expert for an interview, questionnaire, or focused research discussion?
I provide evidence-based insight on cell and gene therapy, mRNA, CRISPR, AAV/LV viral vectors, preclinical strategy, Discovery-to-IND, and Chinas biotech and pharmaceutical landscape.
The basic service includes review of one focused topic and your questions, one 60-minute expert interview or structured discussion, and concise follow-up clarification when needed.
I am a Ph.D. virologist and independent biotech consultant with 15+ years across life-science research and industry. I have led an advanced-therapy program through China and U.S. IND milestones and built an mRNA design and evaluation platform.
Please share the topic, intended audience, format, and questions before ordering so I can confirm fit and scope.
I discuss only public information and general professional knowledge. I do not disclose confidential or nonpublic information from former employers, clients, or third parties. This service does not provide legal, medical, IP/FTO, investment, or formal regulatory advice.
Purpose:
Competitive analysis
•
Market trends
•
Product research
Industry:
Medical & pharmaceutical
•
Science
Research method:
Interviews
FAQ
What topics can you discuss?
Cell and gene therapy, mRNA, CRISPR, AAV/LV vectors, preclinical and IND strategy, biotech product and market questions, and China biotech/pharma context—subject to fit and public-information boundaries.
Can you complete a questionnaire instead of a live call?
Yes. I can review and answer a focused questionnaire when the scope fits one hour of expert work. Larger or evidence-heavy requests should be quoted separately before ordering.
What information is outside scope?
I will not discuss confidential or nonpublic information, MNPI, patient-level or restricted genomic data. I do not provide legal, medical, IP/FTO, investment, or formal regulatory advice.
